Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The T-cell surface glycoprotein CD8 alpha chain (CD8α) is an integral membrane glycoprotein that functions as a co-receptor on T cells, primarily cytotoxic T lymphocytes (CTLs). It enhances T-cell receptor (TCR) recognition of peptide antigens presented by MHC class I molecules on antigen-presenting cells, facilitating efficient cell–cell interactions and signal transduction. CD8α exists as a homodimer (CD8αα) or a heterodimer with a beta chain (CD8αβ). It plays crucial roles in thymocyte development, maturation, and modulation of immune responses. CD8 is widely used as an immunophenotyping marker and is a key component in engineered T-cell therapies such as CAR T-cells.
Enhances T-cell receptor (TCR) signaling upon binding to MHC class I molecules presenting antigens; recruits Lck kinase for signal transduction; mediates cell-cell adhesion during immune responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-cell surface glycoprotein CD8 alpha chain (CD8α).